165 related articles for article (PubMed ID: 18417875)
1. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes.
Varma N; Varma S
Indian J Pathol Microbiol; 2008; 51(1):97-101. PubMed ID: 18417875
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems.
Rubio-Felix D; Giraldo P; Franco E; Gimeno J; Giralt M
Hematol Oncol; 1995; 13(3):139-52. PubMed ID: 7622144
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
[TBL] [Abstract][Full Text] [Related]
4. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
5. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
6. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
7. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
8. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A
Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080
[TBL] [Abstract][Full Text] [Related]
9. Serum deoxythymidine kinase in myelodysplastic syndromes.
Aul C; Gattermann N; Germing U; Winkelmann M; Heyll A; Runde V; Schneider W
Cancer; 1994 Jan; 73(2):322-7. PubMed ID: 8293395
[TBL] [Abstract][Full Text] [Related]
10. Clinico-pathological analysis of myelodysplastic syndromes according to French-American-British classification and international prognostic scoring system.
Lau LG; Chng WJ; Liu TC; Tan LK; Ong KH; Mow BM; Kueh YK
Ann Acad Med Singap; 2004 Sep; 33(5):589-95. PubMed ID: 15531954
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
12. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients.
Maschek H; Gutzmer R; Choritz H; Georgii A
Eur J Haematol; 1994 Nov; 53(5):280-7. PubMed ID: 7813708
[TBL] [Abstract][Full Text] [Related]
13. [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].
Wei J; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):305-11. PubMed ID: 18426654
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases.
Foucar K; Langdon RM; Armitage JO; Olson DB; Carroll TJ
Cancer; 1985 Aug; 56(3):553-61. PubMed ID: 3891071
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic values of in vitro culture growth patterns of marrow granulocyte-macrophage progenitors in patients with myelodysplastic syndrome.
Shih LY; Chiu WF; Lee CT
Leukemia; 1991 Dec; 5(12):1092-8. PubMed ID: 1774958
[TBL] [Abstract][Full Text] [Related]
16. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis.
Mihara K; Chowdhury M; Nakaju N; Hidani S; Ihara A; Hyodo H; Yasunaga S; Takihara Y; Kimura A
Blood; 2006 Jan; 107(1):305-8. PubMed ID: 16160010
[TBL] [Abstract][Full Text] [Related]
17. [Prediction of survival in myelodysplastic syndrome. Analysis of 2 scoring systems with prognostic value].
Sanz GF; Sanz MA; Vallespí T; Cañizo MC; García S; Torrabadella M; San Miguel JF; Irriguible D
Sangre (Barc); 1989 Feb; 34(1):41-6. PubMed ID: 2711284
[TBL] [Abstract][Full Text] [Related]
18. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
19. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.
Suciu S; Kuse R; Weh HJ; Hossfeld DK
Cancer Genet Cytogenet; 1990 Jan; 44(1):15-26. PubMed ID: 2293879
[TBL] [Abstract][Full Text] [Related]
20. [The International Prognostic Scoring System for primary myelodysplastic syndrome].
Sisková M; Dohnalová A; Neuwirtová R; Pĕnicková J; Karban J; Cmunt E
Sb Lek; 2002; 103(3):333-8. PubMed ID: 12688177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
